ANS Biotech is pleased to announce that Julie Chamalet (Business Developer) and Yassine Darbaky (Chief Business Officer) will represent the company at BioFIT 2024, taking place in Lille on December 3-4.
BioFIT is one of Europe’s leading events dedicated to innovation in life sciences, bringing together industry leaders across biotech and pharma who are committed to advancing research and development.
As proud members of AFSSI, we’re delighted to be part of the AFSSI pavilion at BioFIT, and we sincerely appreciate their support in making this collaboration possible.
ALGOGram™ 2.0: Enhancing analgesic development with comprehensive Efficacy and Safety profiling
At ANS Biotech, our commitment to preclinical pain pharmacology drives us to develop tools that make a difference. We are excited to present ALGOGram™ 2.0, our advanced in vivo screening platform tailored specifically for pain research.
By combining efficacy and safety profiling, ALGOGram™ 2.0 offers a complete assessment of analgesic candidates, providing our partners with precise, actionable insights that contribute to the development of safer and more effective pain therapies.
Interested in innovative approaches to Analgesic Development?
We invite you to connect with Julie and Yassine at BioFIT 2024 to discuss collaboration opportunities in the field of pain and learn how ALGOGram™ 2.0 can add value to your research and development projects.
👉 About BioFIT:
BioFIT is one of Europe’s leading events dedicated to innovation in life sciences, focusing on R&D partnerships and the promotion of innovative projects.
We look forward to seeing you in Lille for BioFIT 2024!